FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2015-05-26
Target enrollment:
Participant gender:
Summary
The purpose of this phase I study to determine the optimal dose for the combination of
IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin)
chemotherapy in patients with pancreatic cancer.